Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(1.12)
# 3,550
Out of 4,851 analysts
29
Total ratings
36%
Success rate
-12.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $1.78 | +180.90% | 1 | Apr 29, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $204 → $205 | $187.25 | +9.48% | 3 | Apr 28, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $7.69 | +199.09% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $2.18 | +175.23% | 2 | Dec 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $706 | $580.10 | +21.70% | 4 | Nov 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $38.87 | +337.36% | 9 | Nov 7, 2024 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $65 | $5.90 | +1,001.69% | 2 | Aug 26, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $4.36 | +358.72% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $130.91 | +57.36% | 1 | Aug 12, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $62 → $66 | $45.29 | +45.73% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.47 | +1,396.60% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $1.48 | +575.68% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $13.57 | +342.15% | 1 | Oct 5, 2022 |
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $1.78
Upside: +180.90%
AbbVie
Apr 28, 2025
Maintains: Outperform
Price Target: $204 → $205
Current: $187.25
Upside: +9.48%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $7.69
Upside: +199.09%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.18
Upside: +175.23%
argenx SE
Nov 21, 2024
Maintains: Outperform
Price Target: $675 → $706
Current: $580.10
Upside: +21.70%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $38.87
Upside: +337.36%
Jasper Therapeutics
Aug 26, 2024
Maintains: Outperform
Price Target: $65
Current: $5.90
Upside: +1,001.69%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.36
Upside: +358.72%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $130.91
Upside: +57.36%
Mirum Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $62 → $66
Current: $45.29
Upside: +45.73%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $1.47
Upside: +1,396.60%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $1.48
Upside: +575.68%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $13.57
Upside: +342.15%